FollowPlay Earnings CallPlay Earnings Call
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Pharmaceuticals, Inc. Citi’s Biopharma Back to School Conference September 3, 2025 4:00 PM EDT
Company Participants
Jacob Chacko – President, CEO & Director
Dominic Piscitelli – Chief Financial Officer
Conference Call Participants
Yigal Nochomovitz – Citigroup Inc., Research Division
Presentation
Yigal Nochomovitz
Director and SMid Cap Biotech Analyst
Welcome back everyone. This is final session of the second day of the Biopharma Back to School Summit. So hopefully, everyone has sharpened pencils and is taking good notes. So I’m Yigal Nochomovitz, biotech analyst here at Citi. Next company is ORIC Pharmaceuticals. I’ve been covering them for many years following the progress. And I’m pleased to introduce Jacob Chacko, the CEO of the company and of course, Dominic Piscitelli, the CFO. So welcome, Jacob and Dom. Thank you both for participating.
So I guess maybe to start out, if you wouldn’t mind, just giving just an overview of the pipeline and what are some of the key objectives of the company. And you recently bolstered the balance sheet, as I understand, so you got a little more runway. So tell us about just what are the key — and the key readouts, which we’ll, of course, get into a lot more detail.
Jacob Chacko
President, CEO & Director
Sure. I’m happy to jump in here, Yigal, and I’ll keep it short because I know you have a lot of detailed questions In the pipeline. So ORIC is a clinical stage oncology company. ORIC stands for Overcoming Resistance in Cancer. In a nutshell, that’s the mission of the company. We — obviously, cancer is a very, very large area. So within oncology, we tend to specialize primarily in small molecule drug development in solid tumors, specifically prostate cancer and lung cancer.
So we have 2 clinical stage programs
GIPHY App Key not set. Please check settings